| 
																	
																	
																		 Connection
 
																		 Co-Authors
																		
																	 
																		This is a "connection" page, showing publications co-authored by   Colleen McIlvennan   and   Robert Page.    
																		
																	 
																			
																					
					
					
		
			
			
			|  | 
				
					|  | Connection Strength |  |  
					|  |   |  |  
					|  | 1.431 |  |  |  |  
		
		
			
				McIlvennan CK, Page RL. Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction: Evidence Meets Practice, Part II. J Cardiovasc Nurs. 2016 Nov/Dec; 31(6):545-554.	
				
				
					Score: 0.536
				
				Ilonze OJ, Helmkamp LJ, McIlvennan CK, Allen LA, Breathett K, Enyi CO, Page RL. Trends in urine drug screening and positivity among patients with heart failure: Insights from a large health system. Am Heart J. 2025 Dec; 290:226-229.	
				
				
					Score: 0.245
				
				Lipsey J, Allen LA, Page RL, Helmkamp LJ, Venechuk G, Trinkley KE, Matlock DD, McIlvennan CK. Association of multimorbidity with guideline-directed medical therapy intensification in heart failure: Findings from the EPIC-HF trial. Heliyon. 2024 Jul 15; 10(13):e34178.	
				
				
					Score: 0.228
				
				Bui QM, Allen LA, Monte AA, Page RL, McIlvennan CK. Amphetamine-positive urine drug screens in the setting of mexiletine use: A case series. J Heart Lung Transplant. 2016 08; 35(8):1045-8.	
				
				
					Score: 0.130
				
				McIlvennan CK, Page RL, Ambardekar AV, Brieke A, Lindenfeld J. Activated partial thromboplastin time overestimates anti-coagulation in left ventricular assist device patients. J Heart Lung Transplant. 2014 Dec; 33(12):1312-4.	
				
				
					Score: 0.116
				
				Bass ME, Kiser TH, Page RL, McIlvennan CK, Allen LA, Wright G, Shakowski C. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis. 2021 Aug; 52(2):517-522.	
				
				
					Score: 0.045
				
				Allen LA, Venechuk G, McIlvennan CK, Page RL, Knoepke CE, Helmkamp LJ, Khazanie P, Peterson PN, Pierce K, Harger G, Thompson JS, Dow TJ, Richards L, Huang J, Strader JR, Trinkley KE, Kao DP, Magid DJ, Buttrick PM, Matlock DD. An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial. Circulation. 2021 02 02; 143(5):427-437.	
				
				
					Score: 0.044
				
				Venechuk GE, Khazanie P, Page RL, Knoepke CE, Helmkamp LJ, Peterson PN, Pierce K, Thompson JS, Huang J, Strader JR, Dow TJ, Richards L, Trinkley KE, Kao DP, McIlvennan CK, Magid DJ, Buttrick PM, Matlock DD, Allen LA. An Electronically delivered, Patient-activation tool for Intensification of medications for Chronic Heart Failure with reduced ejection fraction: Rationale and design of the EPIC-HF trial. Am Heart J. 2020 11; 229:144-155.	
				
				
					Score: 0.044
				
				Deininger KM, Tsunoda SM, Hirsch JD, Anderson H, Lee YM, McIlvennan CK, Page RL, Tran JN, Aquilante CL. National survey of physicians' perspectives on pharmacogenetic testing in solid organ transplantation. Clin Transplant. 2020 10; 34(10):e14037.	
				
				
					Score: 0.043
				 | 
																	
																		
																			
																					       Connection Strength       
  The connection strength for concepts is the sum of the scores for each matching publication.    
 Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
 |